A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands
2021
Acta Pharmaceutica Sinica B
Compounds that selectively modulate multiple targets can provide clinical benefits and are an alternative to traditional highly selective agents for unique targets. High-throughput screening (HTS) for multitarget-directed ligands (MTDLs) using approved drugs, and fragment-based drug design has become a regular strategy to achieve an ideal multitarget combination. However, the unexpected presence of pan-assay interference compounds (PAINS) suspects in the development of MTDLs frequently results
doi:10.1016/j.apsb.2021.02.023
pmid:34900527
pmcid:PMC8642439
fatcat:qrbrayfj75hqfbzlr4fvfclutq